Skip to content
Open access

Src kinase as a molecular contributor to tau pathology in Alzheimer’s disease

Oct 2026 · Acta Neuropathologica Communications · 0 citations

TL;DR

Data support Src as a molecular contributor to Tau pathology in AD, operating at early disease stages, and highlight a potential NEUROD2–Src–Tau axis as a candidate pathway contributing to early pathology.

Abstract

Tau pathology is a defining feature of Alzheimer’s disease (AD), yet the molecular factors that modulate its onset and progression remain incompletely understood. The proto-oncogene Src kinase, a non-receptor tyrosine kinase with broad roles in neuronal signaling, has been implicated in neurodegenerative processes, but its relationship to Tau pathology is not fully defined. We examined the spatial and molecular associations between Src and pathological Tau using immunohistochemistry, proteomics, and single-nucleus RNA sequencing in human postmortem brain tissue. Brownian dynamics simulations were performed to test whether Src interacts differentially with Tau conformations. Finally, we tested the effects of Src knockdown on Tau phosphorylation in PS19 transgenic mouse neurons. Src was significantly upregulated in multiple AD-associated brain regions and was highly expressed in vulnerable excitatory neurons. Network-based transcriptomic analysis identified NEUROD2 as a hub transcription factor within the Src-containing subnetwork, with both NEUROD2 and Src significantly upregulated in AD excitatory neurons, and NEUROD2 was validated by immunohistochemistry. Src strongly colocalized with early pathological Tau epitopes, most notably MC1. Mass spectrometry revealed increased phosphorylation of Src at Ser75, Tyr187, and Tyr439 in AD cases. Brownian dynamics simulations indicated a ~ 7-fold increase in Src–Tau contacts when Tau is in paired helical filament conformation compared to microtubule-bound Tau. Functionally, Src knockdown in PS19 hippocampal neurons reduced AT8-positivity. These data support Src as a molecular contributor to Tau pathology in AD, operating at early disease stages. While further studies are needed to establish causality in vivo, our findings highlight a potential NEUROD2–Src–Tau axis as a candidate pathway contributing to early pathology.

Read PDF

Similar papers

Open access Oct 2026

Serine-65 phosphorylated ubiquitin associates with soluble tau and seeding activity in Alzheimer’s disease

Tau propagation is a key driver of Alzheimer’s disease (AD), yet selective markers of seeding-competent tau remain elusive. Ubiquitin phosphorylated at Serine-65 (pS65-Ub) is a PINK1-derived cellular stress signal that accumulates in AD with elevated tau pathology, but its relationship to tau seeding is unknown. Here,...

Ting-Xiang Yan, Xu Hou, J. Watzlawik et al. · 0 citations
Review Open access Oct 2026

Fyn kinase: a key mechanistic regulator and therapeutic target in tauopathy and neurodegenerative diseases

Synaptic dysfunction and intracellular accumulation of pathological tau are convergent hallmarks of Alzheimer’s disease (AD) and related tauopathies, yet the molecular mechanisms coupling these events to widespread neurodegeneration remain incompletely understood. The Src family kinase Fyn has emerged as a critical sig...

Hai-Wen Wang, Xing Fan, Jian-Chao Ping et al. · 0 citations
Open access Nov 2026

Novel Tau Interaction Partners as Potential Biomarkers and Therapeutic Targets in Neurodegenerative Diseases

Alzheimer’s disease is a progressive neurodegenerative disorder leading to cognitive decline and ultimately death. One of the main hallmarks of this disease is the accumulation of pathological tau protein into neurofibrillary tangles. To better understand these pathological mechanisms, it is essential to characterize t...

Karoline Pichlerová, J. Šinský, S. Njemoga et al. · 0 citations
Review Open access Oct 2026

Tau phosphorylation from neuronal adaptation to Alzheimer's disease.

Tau phosphorylation is classically associated with neurodegeneration, yet similar phosphorylation patterns emerge during physiological states and acute stress responses. How these overlapping patterns of phosphorylated Tau (pTau) relate to neuronal adaptation and Alzheimer's disease pathology remains unresolved. We syn...

Ryan Trouvé, P. Verstreken, M. Hoekstra · 0 citations
Review Oct 2026

Selective neuronal vulnerability in Alzheimer's disease: mechanisms, biomarkers, and therapeutic implications.

Alzheimer's disease (AD) is characterized by marked heterogeneity in the timing and extent of neuronal dysfunction and degeneration. Specific neuronal populations, including entorhinal cortex layer II stellate cells, hippocampal CA1 pyramidal neurons, basal forebrain cholinergic neurons, locus coeruleus noradrenergic n...

Tian-Yang Xu, E. Er-deng, Ting Zhang et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.